← All trials
NCT04897893
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 21, 2021
- Primary completion
- Mar 26, 2022
- Completion date
- Mar 26, 2022
- First posted
- May 24, 2021
- Last posted
- Jun 3, 2021
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- SCF PharmaLead sponsor
- SCF PharmaOverall official - principal investigator
- Integrated Health and Social Services Centres (CISSS) de la GaspésieCollaborator
- Integrated Health and Social Services Centres (CISSS) du Bas-St-LaurentCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.